Dor Biopharma Inc | TalkMarkets

Latest Posts

Soligenix Announces Positive Top-line Results For Its Pivotal Phase 3 FLASH Trial Evaluating SGX301 In Treatment Of Cutaneous T-Cell Lymphoma

Article By: TalkMarkets Newswire

Thursday, March 19, 2020 6:32 AM EDT

Soligenix announced positive preliminary top-line results for its pivotal Phase 3 FLASH trial evaluating SGX301 in the treatment of cutaneous T-cell lymphoma. The company will host an Investor Conference Call today at 8:30AM EDT,

In this article: SNGX

Read

Soligenix: Biotech Company Chosen By Italian Hedge Fund BxWorld

Article By: Graziano Martini

Wednesday, July 19, 2017 11:36 PM EDT

BxWorld Fund entered a position in Soligenix (ticker SNGX), a biotech company with some interesting products for the cure of cancer and a range of products against bioterrorism and radioactive warfare.

In this article: SNGX

Read

Week In Review: China's Luxin Invests In $215 Million Funding For Intarcia's Long-Term Diabetes Device

Article By: ChinaBio® Today

Saturday, September 17, 2016 2:30 PM EDT

Luxin Venture Capital of Shandong Province participated in the first closing of the latest funding round for Boston's Intarcia Therapeutics.

In this article: GSK, CUR, SCLN, SNGX, BGNE

Read

Soligenix And Rare Diseases

Article By: Anthony Alfidi

Wednesday, February 3, 2016 7:26 AM EDT

Several US government research agreements support Soligenix's development of biodefense products. Using federal research funds is a good move if it keeps the rest of an enterprise moving toward its larger business goals.

In this article: SNGX

Read